Stockscreener 앱 받기
0.4988
4.08%
-0.0212
시간 외 거래:
.51
0.0112
+2.25%
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Tenaya to lay off about one-third of staff, reveals heart gene therapy data - Endpoints News
Top 3 Insider Stock Buys in March-Are They Still Good in April? - MSN
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting - GlobeNewswire
Revolutionary Gene Therapy Transforms Severe Heart Disease Patients in Landmark Trial - Stock Titan
Undervalued Cardiology Stocks to Watch: TNYA, MIST, BBIO, ALNY - GuruFocus
Tenaya Therapeutics IncOn Mar 27, Co Approves Restructuring PlanSEC Filing - MarketScreener
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - MSN
FY2025 Earnings Estimate for TNYA Issued By Chardan Capital - Defense World
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo
Top 3 Insider Stock Buys in March—Are They Still Good in April? - Benzinga
Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function - Yahoo Finance
Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - simplywall.st
Tenaya reports promising gene therapy for heart condition By Investing.com - Investing.com South Africa
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial - MarketScreener
Tenaya reports promising gene therapy for heart condition - Investing.com India
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo Finance
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models - GlobeNewswire
Revolutionary Heart Disease Treatment: Gene Therapy Reverses Cardiac Damage in Landmark Study - Stock Titan
Tenaya Therapeutics announces $300M mixed shelf offering; shares down - MSN
Tenaya Therapeutics files for mixed shelf offering of up to $300 mln -March 21, 2025 at 04:16 pm EDT - MarketScreener
Tenaya Therapeutics to Present New Data on MYBPC3-Associated Hypertrophic Cardiomyopathy at ACC 2025 Annual Scientific Session - Nasdaq
Tenaya Therapeutics Announces Late Breaker and New Data - GlobeNewswire
Major Breakthrough: Tenaya's Gene Therapy Trial Reveals Critical One-Year Heart Disease Data - StockTitan
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Canaccord Genuity Group Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $6.00 - Defense World
Analysts Issue Forecasts for TNYA Q1 Earnings - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Morgan Stanley Has Lowered Expectations for Tenaya Therapeutics (NASDAQ:TNYA) Stock Price - Defense World
Chardan Capital Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $9.00 - Defense World
What is HC Wainwright’s Estimate for TNYA Q1 Earnings? - Defense World
Canaccord cuts Tenaya Therapeutics price target to $6 By Investing.com - Investing.com South Africa
Canaccord cuts Tenaya Therapeutics price target to $6 - Investing.com
Q1 Earnings Forecast for TNYA Issued By Lifesci Capital - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Chardan Adjusts Price Target on Tenaya Therapeutics to $9 From $18, Keeps Buy Rating - Marketscreener.com
H.C. Wainwright cuts Tenaya Therapeutics price target to $5 By Investing.com - Investing.com Canada
Tenaya Therapeutics Advances Gene Therapy Pipeline - TipRanks
H.C. Wainwright cuts Tenaya Therapeutics price target to $5 - Investing.com
Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.
Tenaya Therapeutics SVP sells shares worth $1,334 By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 By Investing.com - Investing.com Australia
Tenaya Therapeutics chief medical officer sells shares worth $3,982 By Investing.com - Investing.com South Africa
Tenaya Therapeutics chief medical officer sells shares worth $3,982 - Investing.com India
Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 - Investing.com India
3.01%
자본화:
|
볼륨(24시간):